1	The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the
2	outbreak on board the Diamond Princess cruise ship in Japan
3	
4	Sakiko Tabata, M.D. ^{1†} , Kazuo Imai, M.D. ^{1,2*†} , Shuichi Kawano, M.D. ^{1,4} , Mayu Ikeda, M.D. ¹ ,
5	Tatsuya Kodama, M.D. ¹ , Kazuyasu Miyoshi, M.D. ¹ , Hirofumi Obinata, M.D. ^{1,3} , Satoshi Mimura,
6	M.D. ¹ , Tsutomu Kodera, M.D. ¹ , Manabu Kitagaki, M.D. ¹ , Michiya Sato, M.D. ¹ , Satoshi Suzuki,
7	M.D. ¹ , Toshimitsu Ito, M.D. ¹ , Yasuhide Uwabe, M.D. ¹ , Kaku Tamura, M.D. ¹
8	
9	
10	1 Self-Defense Forces Central Hospital, 24-2-1, Ikejiri, Setagaya-ku, Tokyo, Japan
11	2 Department of Infectious Disease and Infection Control, Saitama Medical University, 38 Moro,
12	Hongo, Iruma-gun, Saitama, Japan
13	3 Department of Emergency and Critical Care Medicine, Nippon Medical School, 1-1-5, Sendagi,
14	Bunkyo-ku, Tokyo, Japan
15	4 Japan Ground Self-Defense Force Medical Service School, 24-2-1, Ikejiri, Setagaya-ku, Tokyo,
16	Japan
17	
18	* Corresponding author
19	†Both authors contributed equally
20	
21	Corresponding author
22	Kazuo Imai, M.D.
23	Self-Defense Forces Central Hospital, 24-2-1, Ikejiri, Setagaya-ku, Tokyo, Japan
24	Department of Infectious Disease and Infection Control, Saitama Medical University, 38 Moro,
25	Hongo, Iruma-gun, Saitama, Japan

- 26 E-mail: k_imai@saitama-med.ac.jp
- 27 Tel: 03-3411-0151 or 049-276-111

28 Abstract

- 29 **Background:** The ongoing outbreak of the coronavirus disease 2019 (COVID-19) is a global threat.
- 30 Identification of markers for symptom onset and disease progression is a pressing issue. We
- 31 compared the clinical features on admission among patients who were diagnosed with asymptomatic,
- mild, and severe COVID-19 at the end of observation.
- 33 Methods: This retrospective, single-center study included 104 patients with laboratory-confirmed
- 34 COVID-19 from the mass infection on the Diamond Princess cruise ship from February 11 to
- ³⁵ February 25, 2020. Clinical records, laboratory data, and radiological findings were analyzed.
- ³⁶ Clinical outcomes were followed up until February 26, 2020. Clinical features on admission were
- 37 compared among those with different disease severity at the end of observation. Univariate analysis
- 38 identified factors associated with symptom onset and disease progression.
- Findings: The median age was 68 years, and 54 patients were male. Briefly, 43, 41, and 20 patients
- 40 on admission and 33, 43, and 28 patients at the end of observation had asymptomatic, mild, and
- 41 severe COVID-19, respectively. Serum lactate hydrogenase levels were significantly higher in 10
- 42 patients who were asymptomatic on admission but developed symptomatic COVID-19 compared
- 43 with 33 patients who remained asymptomatic throughout the observation period. Older age,
- 44 consolidation on chest computed tomography, and lymphopenia on admission were more frequent in
- 45 patients with severe COVID-19 than those with mild COVID-19 at the end of observation.
- 46 **Interpretation:** Lactate dehydrogenase level is a potential predictor of symptom onset in COVID-19.
- 47 Older age, consolidation on chest CT images, and lymphopenia might be risk factors for disease
- 48 progression of COVID-19 and contribute to the clinical management.
- 49 **Funding:** Not applicable.

50 Research in context

51 Evidence before this study

- 52 We searched the PubMed database from its inception until March 1, 2020, for articles published in
- 53 English using the keywords "novel coronavirus," "2019 novel coronavirus," "2019-nCoV," "Severe
- acute respiratory syndrome coronavirus 2," "SARS-CoV2," "COVID-19," "mass infection," "herd
- ⁵⁵ infection," "cruise ship," "Diamond Princess," "asymptomatic," and "subclinical." There were no
- 56 published clinical studies featuring COVID-19 as a result of mass infection on board a cruise ship.
- 57 We found published articles entitled "Characteristics of COVID-19 infection in Beijing" and
- ⁵⁸ "Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive
- 59 study," which compared patients with asymptomatic, mild, and severe COVID-19. However, none of
- 60 the studies described potential markers for symptom onset or disease progression in patients with
- 61 COVID-19.

62 Added value of this study

- 63 We present the differences in clinical characteristics of 104 patients with laboratory-confirmed
- 64 COVID-19 as a result of mass infection on the Diamond Princess cruise ship who were treated at
- 65 Self-Defense Forces Central Hospital, Japan from February 11 to February 25, 2020. On admission,
- 43, 41, and 20 patients had asymptomatic, mild, and severe COVID-19, respectively, whereas 33, 43,
- and 28 patients were determined to have asymptomatic, mild, and severe COVID-19, respectively, at
- the end of observation. During the observation period, 10 of the 43 (23.3%) asymptomatic patients
- on admission developed symptoms of COVID-19. Conversely, eight of the 84 (9.5%) patients with
- asymptomatic and mild COVID-19 on admission developed severe disease during the observation
- period. The serum lactate dehydrogenase (LDH) levels were significantly higher in 10 patients who
- were initially asymptomatic on admission to the hospital and developed symptomatic COVID-19
- during the observation period compared with 33 patients who remained asymptomatic throughout the
- ⁷⁴ observation period. The prevalence rates of consolidation on chest computed tomography (CT)
- ⁷⁵ images and lymphopenia were significantly higher in eight patients who developed severe
- ⁷⁶ COVID-19 during the observation period compared with the 76 patients with asymptomatic or mild
- disease at the end of the observation. Older age, consolidation on chest CT, and lymphopenia on
- admission were more frequent in patients with severe COVID-19 (n = 28) than those with mild
- COVID-19 (n = 43) at the end of observation. LDH level might be marker for symptom onset in
- 80 patients with COVID-19, whereas older age, consolidation on chest CT imaging, and lymphopenia
- are potential risk factors for disease progression. The current report findings will contribute to the
- 82 improvement of clinical management in patients with COVID-19.
- 83 Implications of all the available evidence
- 84 Serum LDH level is a potential predictor of symptom onset of COVID-19, whereas older age,
- consolidation on chest CT imaging, and lymphopenia have potential utility as markers for disease
- 86 progression.
- 87

88 Introduction

- 89 The coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus severe acute
- 90 respiratory syndrome coronavirus 2 (SARS-CoV2). The first case was reported in Wuhan, China, in
- ⁹¹ December 2019, ¹ and the ongoing outbreak has been declared as a pandemic by the World Health
- 92 Organization. Since specific treatment for COVID-19 is unknown, identification of patients at high
- risk for severe illness is critical to prepare and provide sufficient supportive therapy. Additionally, an
- 94 explosive increase in case numbers has led to the collapse of healthcare systems. Therefore, triage of
- patients and their transportation to proper facilities are necessary. Although our knowledge of the
- 96 clinical characteristics of COVID-19 and the pathogenicity of SARS-CoV2 are increasing, detailed
- 97 clinical characteristics of the disease remain unknown; most of the published studies to date focus on
- 98 patients with severe COVID-19.²⁻⁵ In Japan, a large number of infections occurred among the
- passengers and crew members on board the Diamond Princess cruise ship in February 2020. By
- 100 March 1, 2020, there were approximately 700 patients with laboratory-confirmed SARS-CoV2
- ¹⁰¹ infection. ^{6,7} Approximately 3700 passengers and crew members on the cruise ship were tested for
- 102 SARS-CoV2 by reverse transcription (RT)-polymerase chain reaction (PCR), and all symptomatic
- and asymptomatic cases were referred to medical institutions designated for infectious diseases in
- accordance with the Infectious Diseases Control Law of Japan.^{6,7} Approximately 15% of all
- 105 laboratory-confirmed cases from Diamond Princess were admitted to the Self-Defense Forces
- 106 Central Hospital in Japan.
- 107 In clinical settings, identifying patients who are at risk of symptom onset and clinical deterioration is
- 108 essential. Therefore, understanding the clinical characteristics of patients with COVID-19 of
- 109 different severity is necessary. To that end, we retrospectively analyzed the detailed clinical
- 110 characteristics of hospitalized patients with COVID-19 as a result of the Diamond Princess outbreak,
- including those with asymptomatic, mild, and severe disease presentation, who were treated in the
- 112 Self-Defense Forces Central Hospital in Japan.
- 113

114 Methods

115 Study design and patients

116 We conducted a retrospective review of the medical records of 104 patients with laboratory-confirmed COVID-19 who were admitted to the Self-Defense Forces Central Hospital in 117 118 Japan between February 11 and February 25, 2020. Approximately 3700 passengers on the cruise 119 ship were examined by quantitative RT-PCR or nested RT-PCR for SARS-CoV2 using pharyngeal 120 swabs or sputum specimens at the public health institutes based on the recommendations protocol by the National Institute of Infectious Disease.⁶⁻⁸ This study was reviewed and approved by the Japan 121 Self-Defense Forces Central Hospital (approval number 01-011). Informed consent, both written and 122 123 oral, was obtained from all enrolled patients.

124 Data collection

125 Patient information was retrospectively collected from the hospital medical records and included

- 126 clinical records, laboratory findings, and chest CT images. All data were collected and reviewed by
- 127 two study investigators (ST and KI).

128 **Definitions**

- 129 The geographical regions were classified according to the standard country or area codes for
- 130 statistical use (M49) by the United Nations Statistics Division
- 131 (https://unstats.un.org/unsd/methodology/m49/). Asymptomatic cases were defined as patients with
- 132 no history of clinical signs and symptoms. Severe symptomatic cases were defined as patients
- 133 showing clinical symptoms of pneumonia (dyspnea, tachypnea, peripheral capillary oxygen
- 134 saturation <93%, and need for oxygen therapy). ⁹ Patients with other symptoms were classified as
- 135 mild cases. The observation period was defined as the time interval between the date of admission
- and the date of discharge or February 26, 2020.

137 Statistical analysis

- 138 Continuous variables were expressed as means with standard deviation or medians with interquartile
- range (IQR) and compared using Student's *t* test and Wilcoxon rank-sum test for parametric and
- 140 nonparametric data, respectively. Categorical variables were expressed as numbers (%) and
- 141 compared by the χ^2 or Fisher's exact test. A two-sided *p* value of less than 0.05 was considered to be
- statistically significant. All statistical analyses were calculated using Stata13 (Stata Corp, College
- 143 Station, TX, USA).

144 **Role of the funding source**

- 145 There was no funding source for this study. The corresponding author had full access to all
- study-related data and had final responsibility for the decision to submit the study for publication.
- 147

148 **Results**

- 149 During the observation period, a total of 107 patients on board the Diamond Princess cruise ship with
- 150 laboratory-confirmed COVID-19 were hospitalized in the Self-Defense Forces Central Hospital in
- 151 Japan. Three patients were excluded from the study because of withdrawal of consent to join the
- study. Therefore, the remaining 104 patients were included in the final analysis. The patients' clinical
- history, physical examination, and chest CT findings were evaluated on the day of admission, and all
- blood tests were completed within the first 2 days following admission. The characteristics of 104
- patients are presented in Table 1. Briefly, the patient age ranged from 25 to 93 years (median, 68
- years; IQR, 46.75–75 years), and 54 (51.9%) patients were male. Most of the patients were from
- 157 Eastern Asia, with Japanese and Chinese ethnicities as the majority. The range of observation period
- 158 was 3–15 days (median, 10 days; IQR, 7–10 days). Fifty-two (50.0%) patients had comorbidities.
- 159 Based on their presentation on the day of admission, 43 patients (41.4%) who did not display any
- symptoms were classified as asymptomatic, whereas 41 (39.4%) and 20 (19.2%) patients were
- 161 classified to have mild and severe COVID-19, respectively.
- 162

- 163 The clinical findings of the patients who were symptomatic on the day of admission and at the end of
- observation period are shown in Table 2. At the end of the observation, there were 33 (31.7%), 43
- 165 (41.3%), and 28 (26.9%) patients with confirmed asymptomatic, mild, and severe COVID-19,
- respectively. The most common clinical signs and symptoms on admission among the 71
- 167 symptomatic patients at the end of the observation were fever (42.3%) and cough (40.8%). Of the 43
- 168 patients who were asymptomatic on admission, 10 (23.3%) patients developed symptomatic
- 169 COVID-19 during the observation period, including three (7.0%) patients who developed severe
- 170 COVID-19 and required supplemental oxygen therapy. Conversely, five of the 41 (12.2%) patients
- 171 with mild disease on admission developed severe COVID-19 and required supplemental oxygen
- therapy. Therefore, eight of the 84 (9.5%) patients with asymptomatic or mild presentation on
- admission developed severe COVID-19 during the observation period. Additionally, of the 71
- patients who were symptomatic at the end of the observation, 14 (13.5%) and one (1.4%) patient
- required oxygen therapy and mechanical ventilation, respectively, whereas 10(14.1%) and five
- 176 (7.0%) patients were treated by antibiotics and lopinavir/ritonavir, respectively. There were no
- 177 reports of complications or death during the observation period.
- 178

179 The characteristics of 10 patients who developed symptomatic COVID-19 during the observation

- period among those who were asymptomatic on admission are presented in Table 3. Among these 10
- patients who developed symptomatic COVID-19, the most frequent symptom was cough (n = 7,
- 182 70.0%). Conversely, 17 of the 33 (51.5%) patients never developed symptoms until the end of the
- observation period had abnormal lung findings with various patterns on CT images (Table 3 and
- Figure 1). By univariate analysis, there were no significant differences in the distribution of age, sex,
- and comorbidities or the prevalence of abnormal lung findings and CT patterns between the
- symptomatic and asymptomatic patients. The prevalence of elevated LDH levels above 230 IU/L was
- 187 significantly higher in patients who were initially asymptomatic but developed symptomatic
- 188 COVID-19 during the observation period (50.0% vs 12.1%; odds ratio [OR], 7.25; 95% confidence
- 189 interval [CI], 1.43-36.70; p = 0.02).
- 190

191 In the group of eight patients who developed severe COVID-19 during the observation period, the

age range was 42–87 years (median, 70 years; IQR, 70–77 years), and five (62.5%) patients were

- 193 male. The period from symptom onset to the reclassification of disease presentation as severe
- 194 COVID-19 ranged from 1 to 5 days (median, 4 days; IQR, 2.5–5 days). Additionally, all eight
- 195 patients (100.0%) developed radiographical abnormalities on CT prior to the emergence of
- 196 symptoms of typical pneumonia including tachypnea, dyspnea, and hypoxemia (Figure 2).
- 197 Furthermore, among these patients who developed severe COVID-19 during the observation period,
- 4 (50.0%) and 3 (37.5%) patients lacked the symptoms of cough and fever, respectively. We also
- 199 compared these eight patients who developed severe COVID-19 with 76 patients who remained
- asymptomatic or had mild COVID-19 at the end of the observation period. By univariate analysis, no

- significant differences were observed in the distribution of age, sex, and comorbidities between the
- two groups. The prevalence rates of consolidation (75.0% vs 19.7%; OR, 12.20; 95%CI, 2.23-66.59;
- 203 p = 0.04) and lymphopenia (62.5% vs 25.0%; OR, 5.00; 95%CI, 1.10–22.92; p = 0.04) on the day of
- admission were significantly higher in patients who developed severe COVID-19 during the
- observation period than in those who were asymptomatic or had mild disease at the end of the
- 206 observation period.
- 207
- Finally, we performed analyses to identify differences in the clinical characteristics between patients
- with mild and severe COVID-19 at the end of the observation period (Table 4). By univariate
- analysis, age was significantly higher in the severe COVID-19 group than in the mild COVID-19
- group (median, 72.5 years; IQR, 55.25-76.5 years vs median, 60 years; IQR, 40.0-71.0 years;
- p = 0.03). There were no significant differences in the distribution of sex, comorbidities, clinical
- signs, and symptoms between the two groups. However, there was a significant difference in the
- prevalence of consolidation as a CT pattern between the severe and mild cases (46.4% vs 20.9%; OR,
- 3.27; 95%CI, 1.15-9.30; p = 0.03). Among the blood tests, the rate of lymphopenia was higher in
- 216 patients with severe COVID-19 than in those with mild COVID-19 at the end of the observation
- 217 period (57.1% vs 23.3%; OR, 4.40; 95% CI; 1.57-12.32; p = 0.005).
- 218

219 Discussion

220 The present retrospective, single-center study provides a summary of the clinical features of patients

- who developed COVID-19 of varying severity as a result of mass infection on board a cruise ship.
- 222 The LDH levels were significantly higher in 10 patients who were initially asymptomatic on
- admission to the hospital and developed symptomatic COVID-19 during the observation period than
- in 33 patients who remained asymptomatic throughout the observation period. Older age,
- 225 consolidation on chest CT images, and lymphopenia at the time of admission were significantly more
- frequent among 28 patients with severe COVID-19 than among 43 patients with mild COVID-19 at
- 227 the end of the observation period. Overall, these findings suggest that serum LDH level might be a
- marker of symptom onset and that older age, consolidation on chest CT images, and lymphopenia are
- 229 potential risk factors for disease progression in patients with COVID-19.
- 230

231 The predictors of symptom onset and risk factors for disease progression in COVID-19 remain

- 232 partially unclear because patients who are asymptomatic or are otherwise exhibiting mild symptoms
- do not necessarily visit a hospital. During the COVID-19 outbreak on the Diamond Princess cruise
- ship, approximately 3700 individuals on board were tested for SARS-CoV2 by RT-PCR, and all
- laboratory-confirmed patients were referred to the hospitals. This unique situation allowed us to
- ²³⁶ observe the clinical course of asymptomatic patients as well as those with mild and severe symptoms,
- which has not been reported to date. $^{2-5}$
- 238

- Based on the previously published findings of COVID-19 in China, old age, male sex, and presence
- of comorbidities are considered as potential risk factors for disease progression and poor prognosis.
- ²⁴¹ ^{1,10} Zhou *et al.* indicated that older age, high sequential organ failure assessment score, and elevated
- d-dimer level were potential risk factors for death in patients with COVID-19. ¹¹ Qin *et al.* reported
- that lymphopenia and higher neutrophil–lymphocyte ratio were frequently observed in patients with
- severe COVID-19 compared with those with mild disease. The present study findings support those
- of previous reports suggesting older age and lymphopenia as potential risk factors for disease
- progression in COVID-19. Lymphopenia, a common feature of symptomatic COVID-19, ^{12,13} can be
- a direct consequence of SARS-CoV2 or might be mediated by cytokines. Qin *et al.* also suggested
- that SARS-CoV2 infection might affect T lymphocytes and dysregulate the immune system,
- consequently leading to secondary bacterial infections. ¹⁴ In the present study, we observed
- lymphopenia in 27.3% of the patients who were asymptomatic at the end of observation period,
- which suggests the development of immune system dysregulation as a direct consequence of
- 252 SARS-CoV2 infection in asymptomatic cases. However, the role lymphopenia in asymptomatic
- 253 patients remains unclear. Further cohort studies are warranted to determine the effect of lymphopenia
- caused by SARS-CoV2 infection in the presence of secondary bacterial infection.
- 255
- In the present study, the prevalence of consolidation detected by chest CT was significantly higher in
- severe cases than in mild cases. Consolidation was also frequently detected in patients who
- developed severe COVID-19 during the observation period. Pan *et al.* and Shi *et al.* reported that
- abnormal lung findings varied from ground glass opacities (GGOs) to consolidation during the
- course of COVID-19 and that the appearance of consolidation was more frequent within 1–3 weeks
- after the symptom onset. ^{15,16} Previous studies found that 55% of patients with COVID-19 developed
- dyspnea in a median of 8 days (IQR, 5.0–13.0 days) after symptom onset; ¹ thus, the development of
- consolidation on CT is associated with disease deterioration. Generally, consolidation is easily
- detectable by chest X-ray, which therefore might be useful for the evaluation of risk for disease
- 265 progression in patients with COVID-19 in settings with limited resources.
- 266

Additionally, CT imaging revealed a high prevalence of lung abnormalities in patients with

268 COVID-19. The various patterns of abnormal lung findings were observed in asymptomatic cases

- (51.5%) as well as in symptomatic cases (69.0%) at the end of the observation period. In their report
- focusing on CT imaging findings of COVID-19, Shi *et al.* also noted the presence of abnormal lung
- ²⁷¹ findings in asymptomatic patients. ¹⁶ Bai *et al.* investigated the common radiological characteristics
- of COVID-19 pneumonia and reported that chest CT had a diagnostic sensitivity of 73%–93% and a specificity of 93%–100% in distinguishing COVID-19 from viral pneumonia. ¹⁷ Therefore, chest CT
- specificity of 93%–100% in distinguishing COVID-19 from viral pneumonia.¹⁷ Therefore, chest (imaging might also be useful diagnostic tool for the asymptomatic and symptomatic patients with
- 274 minaging might also be useful diagnostic tool for the asymptomatic and symptomatic patients with
- 275 COVID-19. In the present study, all eight patients who developed severe COVID-19 during the
- observation period presented with CT abnormalities, in advance of the appearance of typical

- 277 pneumonia symptoms such as dyspnea, tachypnea, and hypoxemia. Of these eight patients, four and
- three patients lacked the symptoms of cough and fever, respectively. These findings highlight that
- 279 COVID-19 pneumonia silently progresses without any remarkable symptoms. Conversely, the
- majority of asymptomatic patients with radiological abnormalities on CT imaging did not develop
- severe pneumonia. The differences observed in the clinical outcomes might be associated with
- patient background characteristics as well as the genetic and pathogenic diversity of SARS-CoV2.
- 283 Understanding CT abnormalities relevance to the duration of virus shedding and the incidence of
- secondary bacterial pneumonia is important to improve the clinical management of COVID-19.
- Further investigation is necessary to clarify the clinical impact of CT findings in patients with
- asymptomatic or mild COVID-19.
- 287

288 Interestingly, there was a significant difference in the rate of patients with elevated LDH levels 289 between those who developed symptomatic COVID-19 during the observation period and those who 290 remained asymptomatic throughout the observation period, although there was no significant difference in the prevalence of lymphopenia between the two groups. Elevated serum LDH levels are 291 associated with lung tissue damage, ¹⁸ and serum LDH is considered as a marker for disease activity 292 and progression in pneumonia due to various etiologies.^{19,20} Given that abnormal lung findings are 293 294 frequently observed in patients with asymptomatic COVID-19, these findings implicate that an 295 elevated LDH level might also reflect lung tissue damage by COVID-19 and might be considered as 296 a predictor for symptom onset in COVID-19. Patient assessment with determination of serum LDH 297 levels and chest CT imaging might facilitate the successful dedication of medical resources to 298 patients who are at higher risk for disease progression in the setting of mass infections as well as in 299 normal clinical settings.

300

301 The major limitations of the present study were selection bias and low number of patients. We 302 enrolled an ideal, homogeneous cluster of relatively healthy individuals who could remain on board a 303 cruise ship for a relatively long term. Therefore, the patient population was not an exact 304 representation of normal clinical settings. Triage on the Diamond Princess cruise ship before emergency transportation has also introduced a selection bias with an atypically large number of 305 306 patients. The Self-Defense Forces Central Hospital in Tokyo is close to the Yokohama port where the 307 cruise ship was docked, and the symptomatic cases were referred to the study hospital. However, the 308 critical cases were preferentially referred to neighboring hospitals in Yokohama. Likewise, several 309 clinical signs and symptoms, which have occurred and disappeared before the patients were referred 310 to our hospital, may be included or excluded from this study. In addition, laboratory tests and CT 311 images were obtained once in majority of the patients, and the present study was not able to 312 determine changes in lymphocyte count and radiological findings over the course of observation. 313 Therefore, multicenter, multi-national cohort studies should be conducted to determine predictive 314 markers for symptom onset and risk factors for diseases progression.

9

315	
316	Conclusion
317	The present study highlights the clinical features of patients who developed COVID-19 as a result of
318	mass infection on board the Diamond Princess cruise ship. Our analyses reveal serum LDH level as a
319	potential predictor of symptom onset in COVID-19. Age, consolidation on chest CT images, and
320	lymphopenia might be risk factors for disease progression. These findings contribute to a better
321	understanding of the clinical course and access points to improve disease management in patients
322	with COVID-19. Additional cohort studies are warranted to determine predictors for symptom onset
323	and risk factors for disease progression.
324	
325	Declaration of interests
326	The authors declare that they have no conflicts of interests.
327	
328	Role of the funding source
329	This research did not receive any specific grant from funding agencies in the public, commercial, or
330	nonprofit sectors. The corresponding author had full access to all study-related data and had final
331	responsibility for the decision to submit the study for publication.
332	
333	Authors' contributions
334	TI and KT, study conception and design; ST and KI, collecting data and performing data analysis; ST,
335	KI, MI, and KM manuscript drafting and editing; TaK, HO, SK, TsK, MK and SM, manuscript
336	revision; MS, SS and UY, study supervision. All authors have read and approved the final
337	manuscript.
338	
339	Acknowledgments
340	We thank everyone involved in the COVID-19 management and treatment team from the
341	Self-Defense Forces Central Hospital in Japan and members who were assembled from other
342	institutes of Japan Self-Defense Forces. Particularly, we thank Dr. Koji Kameda, Dr. Takayuki
343	Yamamoto, Dr. Daishi Higashiyama, Dr. Yoshitaka Imoto, Dr. Masataka Miyama, Dr. Tsukasa
344	Mizuno, Dr. Kento Kato, Dr. Mamoru Honda, Dr. Shoji Takeda, and Dr. Masumi Ogawa, Dr. Shingo
345	Tanaka, Dr. Hisashi Sasaki, Dr. Mitsuki Yamaga, Dr. Shinichiro Ota and Dr. Hiroaki Taniguchi for
346	supporting the data collection, and Dr. Akira Fujikawa and Dr. Shohei Inui for the interpretation of
347	chest CT images. We also thank Mr. Shingo Tamaki (School of Tropical Medicine and Global Health,
348	Nagasaki University, Japan) for the supporting statistical analysis, Colonel. Kazuhiro Nakaya

- 349 (Medical Department, Ground Staff Office, Ministry of Defense) for the scientific advice, and Enago
- 350 (www.enago.jp) for the English language review.

351 References

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
 coronavirus in Wuhan, China. *The Lancet* 2020; **395**(10223): 497-506.

Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by
 SARS-CoV-2 in Wuhan, China. *Allergy* 2020. doi: 10.1111/all.14238.

3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of
2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020;
358 395(10223): 507-13.

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**(11):1061-1069.

Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated with Severe and
 Critical COVID-19 Pneumonia. *Investigative Radiology* 2020. doi:
 10.1097/RLI.00000000000672.

- Kakimoto K, Kamiya H, Yamagishi T, Matsui T, Suzuki M, Wakita T. Initial Investigation of
 Transmission of COVID-19 Among Crew Members During Quarantine of a Cruise Ship —
 Yokohama, Japan, February 2020. MMWR Morb Mortal Wkly Rep 2020;69:312-313. DOI:
 http://dx.doi.org/10.15585/mmwr.mm6911e2
- 368 7. National Institute of Infectious Diseases. Field briefing: Diamond Princess COVID-19 cases. 369 Tokyo, Japan: National Institute of Infectious Diseases; 2020. https://www.niid.go.jp/niid/en/2019-ncov-e/9407-covid-dp-fe-01.html 370 [Latest accessed 371 26/Mar/2020]

8. Nao N, Shirato K, Katano H, et al. Detection of second case of 2019-nCoV infection in
Japan. National Institute of Infectious Diseases.

- 374 .https://www.niid.go.jp/niid/images/vir3/nCoV/method-niid-20200123-2_erratum.pdf [Latest
 375 accessed 26/Mar/2020]
- 376 9. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for
 377 2019 novel coronavirus disease in fever clinics. *The Lancet Respiratory Medicine 2020*. doi:
 378 https://doi.org/10.1016/S2213-2600(20)30071-0

Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus
 (COVID-19) infection: a systematic review and meta-analysis. *International Journal of Infectious Diseases* 2020. doi: https://doi.org/10.1016/j.ijid.2020.03.017.

- 382 11. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
 383 with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020. doi:
 384 https://doi.org/10.1016/S0140-6736(20)30566-3.
- Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
 China. *New England Journal of Medicine* 2020. doi: 10.1056/NEJMoa2002032.
- 13. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission
 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.

389 *The Lancet* 2020. doi: https://doi.org/10.1016/S0140-6736(20)30360-3.

Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19
 in Wuhan, China. *Clinical Infectious Diseases* 2020. doi: https://doi.org/10.1093/cid/ciaa248.

Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery
From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology* 2020: 200370. doi:
https://doi.org/10.1148/radiol.2020200370.

Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19
pneumonia in Wuhan, China: a descriptive study. *The Lancet Infectious Diseases*. doi:
https://doi.org/10.1016/S1473-3099(20)30086-4.

Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 398 17. 399 from viral pneumonia on chest CT. Radiology; **0**(0): 200823. doi: 400 https://doi.org/10.1148/radiol.2020200823.

18. Drent M, Cobben N, Henderson R, Wouters E, van Dieijen-Visser M. Usefulness of lactate
dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. *European Respiratory Journal* 1996; 9(8): 1736-42.

404 19. Quist J, Hill AR. Serum Lactate Dehydrogenase (LDH) in Pneumocystis carinii Pneumonia,
 405 Tuberculosis, and Bacterial Pneumonia. *Chest* 1995; **108**(2): 415-8.

Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate Dehydrogenase as a Biomarker for
Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children. *Respiratory care* 2015;
60(10): 1469-75.

409

410

411 Figure Legends

- 412 Figure 1. Computed tomography (CT) patterns of abnormal lung findings among asymptomatic
- 413 patients with the 2019 novel coronavirus disease (COVID-19). (A–D) A 73 year-old female patient.
- 414 Patchy non-segmental GGOs are observed adjacent to the parietal pleura in the right upper lobe (A
- and B) and in both lower lobes (C and D). (E) A 70 year-old female patient. GGO with interlobular
- septal thickening (crazy-paving appearance) adjacent to the parietal pleura in both lower lobes. (F) A
- 417 76 year-old male. CT image shows GGO with consolidation, bronchial wall thickening, and
- 418 bronchiectasis in left lower lobe.
- 419
- 420 Figure 2. Progression of CT findings in a 75 year-old male patient with COVID-19. The patient was
- 421 asymptomatic on the day of admission. On the fourth day of admission, he developed tachypnea and
- 422 hypoxemia and was administered oxygen therapy. (A–C) Chest CT images on the day of admission
- 423 show multifocal GGO adjacent to the parietal pleura in multiple lobes with emphysematous changes.
- 424 (D–F) Follow-up chest CT images on the tenth day of admission show an increase in the extent of
- 425 GGO with crazy-paving appearance.

Total number of patients ((n = 104)
Characteristics	
Age	68 [46.75–75]
Sex (male)	54 (51.9%)
Observation period (days)	10 [7–10]
Time from onset to admission (days)	5 [2-7]
Nationality	
Eastern Asia	55 (52.9%)
Southeast Asia	21 (20.2%)
Europe	4 (3.8%)
Northern America	14 (13.5%)
Oceania	4 (3.8%)
Others	6 (5.8%)
Smoking	
Yes	18 (17.3%)
Comorbid condition	
Total	52 (50.0%)
Cardiovascular disease	31 (29.8%)
Endocrine disorder	9 (8.7%)
Diabetes mellitus	7 (6.7%)
Respiratory disorder	7 (6.7%)
Malignancy	4 (3.8%)
Severity on admission	
Asymptomatic	43 (41.4%)
Mild	41 (39.4%)
Severe	20 (19.2%)

Table 1. Baseline characteristics of patients with COVID-19 on the Diamond Princess cruise
 ship

428 Data are presented as n (%), or median [interquartile range], unless otherwise specified.

	Number (%)		
	On admission	At the end of observation	
Signs and symptoms			
Fever	30 (42.3%)	36 (50.7%)	
Cough	29 (40.8%)	43 (60.6%)	
Malaise	12 (16.9%)	22 (31.0%)	
Headache	10 (14.1%)	18 (25.4%)	
Sore throat	11 (15.5%)	11 (15.5%)	
Runny nose	16 (22.5%)	24 (33.8%)	
Diarrhea	8 (11.3%)	10 (14.1%)	
Dyspnea	7 (9.9%)	19 (26.8%)	
Tachypnea	16 (22.5%)	24 (33.8%)	
$SpO_2 < 93\%$	3 (4.2%)	14 (19.7%)	
Treatment			
Acetaminophen	4 (5.6%)	15 (21.1%)	
NSAIDs	-	1 (1.4%)	
Antibiotics	-	10 (14.1%)	
Lopinavir/ritonavir	-	5 (7.0%)	
Oxygen therapy	3 (4.2%)	14 (19.7%)	
Mechanical ventilation	-	1 (1.4%)	
Severity			
Asymptomatic	10(14.1%)	-	
Mild	41 (57.7%)	43 (60.6%)	
Severe	20 (28.2%)	28 (39.4%)	

429 Table 2. Clinical findings and disease severity of 71 patients with symptomatic COVID-19

430 Data are presented as n (%).

431 NSAID, non-steroidal anti-inflammatory drug; SpO₂, peripheral capillary oxygen saturation

	Total	At the end of observation			OR
	n = 43	Asymptomatic	Symptomatic	<i>p</i> value	(95% CI)
		n = 33	n = 10		
Characteristics					
A	69	70	67.5	0.96	
Age	[60.5–75]	[57–75]	[66·25–73·5]	0.90	
Sex (male)	19 (44.2%)	15 (45.5%)	4 (40.0%)	1.00	
Smoking					
Yes	7 (16.3%)	5 (15.2%)	2 (20.0%)	0.65	
Comorbid condition					
Total	21 (48.8%)	15 (45.5%)	6 (60.0%)	0.48	
Cardiovascular disease	12 (27.9%)	9 (27.3%)	3 (30.0%)	1.00	
Endocrine disorder	3 (7.0%)	2 (6.1%)	1 (10.0%)	0.56	
Diabetes mellitus	5 (11.6%)	5 (15.2%)	-	0.32	
Respiratory disorder	4 (9.3%)	2 (6.1%)	2 (20.0%)	0.22	
Malignancy	2 (4.7%)	1 (3.0%)	1 (10.0%)	0.42	
Signs and symptoms					
Fever	3 (7.0%)	-	3 (30.0%)	-	
Cough	7 (16.3%)	-	7 (70.0%)	-	
Malaise	2 (4.7%)	-	2 (20.0%)	-	
Headache	2 (4.7%)	-	2 (20.0%)	-	
Sore throat	-	-	-	-	
Runny nose	-	-	-	-	
Diarrhea	1 (2.3%)	-	1 (10.0%)	-	
Dyspnea	3 (7.0%)	-	3 (30.0%)	-	
Tachypnea	3 (7.0%)	-	3 (30.0%)	-	
$SpO_2 < 93\%$	3 (7.0%)	-	3 (30.0%)	-	
Radiographically findings of	on admission				
Abnormal lung findings	25 (58.1%)	17 (51.5%)	8 (80.0%)	0.15	
Lateral	13 (30.2%)	10 (30.3%)	3 (30.0%)	-	
Bilateral	12 (27.9%)	7 (21.2%)	5 (50.0%)	0.11	
GGO	15 (34.9%)	11 (33·3%)	4 (40.0%)	0.72	
Multifocal GGO	12 (27.9%)	9 (27.3%)	3 (30.0%)	1.00	
Consolidation	9 (20.9%)	6 (18·2%)	3 (30.0%)	0.41	
Crazy-paving appearance	5 (11.6%)	2 (6.1%)	3 (30.0%)	0.07	

432 Table 3. Clinical characteristics of 43 asymptomatic patients on admission

Nodular lesion Laboratory findings on adr	3 (7·0%)	2 (6.1%)	1 (10.0%)	0.56	
·		2(0,10/)	1 (10 00/)	1.00	
AST > 38 (IU/L)	4 (9.3%)	3 (9.1%)	1 (10.0%)	1.00	
ALT > 45 (IU/L)	5 (11.6%)	4 (12.1%)	1 (10.0%)	1.00	
LDH > 230 (IU/L)	9 (20.9%)	4 (12.1%)	5 (50.0%)	0.02*	7·25 (1·43–36·70)
CRP > 1.0 (mg/dL)	18 (41.9%)	11 (33.3%)	7 (70.0%)	0.07	
White blood cell count <4000 (/µL)	6 (14.0%)	4 (12.1%)	2 (20.0%)	0.61	
Platelet count <15 (×10 ⁴ /µL)	2 (4.7%)	1 (3.0%)	1 (10.0%)	0.41	
Lymphocyte count <1200 (/µL)	13 (30·2%)	9 (27.3%)	4 (40.0%)	0.46	

433 Data are presented as n (%), or median [interquartile range], unless otherwise specified.

434 Asterisk indicates statistical significance.

435 OR, odds ratio; 95% CI, 95% confidence interval; GGO, ground glass opacity; AST, aspartate

436 aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C reactive

437 protein

439	observation
400	UDSCI VALIUII

	Total n = 71	Mild n = 43	Severe	p value	OR (95% CI)
			n = 28		
Characteristics					
A	67	60	72.5	0.03*	
Age	[44–75]	[40–71]	[55.25-76.5]	0.03*	
Sex (male)	39 (54.9%)	22 (51.2%)	17 (60.7%)	0.47	
Smoking					
Yes	13 (18.3%)	6 (14.0%)	7 (25.0%)	0.35	
Comorbid condition					
Total	37 (52.1%)	19 (44.2%)	18 (64.3%)	0.14	
Cardiovascular disease	22 (31.0%)	11 (25.6%)	11 (39.3%)	0.3	
Endocrine disorder	7 (9.9%)	3 (7.0%)	4 (14.3%)	0.42	
Diabetes mellitus	2 (2.8%)	1 (2.3%)	1 (3.6%)	1.00	
Respiratory disorder	5 (7.0%)	2 (4.7%)	3 (10.7%)	0.38	
Malignancy	3 (4.2%)	2 (4.7%)	1 (3.6%)	1.00	
Acetaminophen on admissi	on				
Yes	4 (5.6%)	4 (9.3%)	-	0.15	
Signs and symptoms on adu	mission				
Fever	30 (42.3%)	19 (44.2%)	11 (39.3%)	0.8	
Cough	29 (40.8%)	16 (37.2%)	13 (46.4%)	0.49	
Malaise	12 (16.9%)	6 (14.0%)	6 (21.4%)	0.52	
Headache	10 (14.1%)	8 (18.6%)	2 (7.1%)	0.3	
Sore throat	11 (15.5%)	7 (16.3%)	4 (14.3%)	1.00	
Runny nose	16 (22.5%)	8 (18.6%)	8 (28.6%)	0.39	
Diarrhea	8 (11.3%)	5 (11.6%)	3 (10.7%)	1.00	
Dyspnea	7 (9.9%)	-	7 (25.0%)	-	
Tachypnea	16 (22.5%)	-	16 (57.1%)	-	
$SpO_2 < 9\%$	3 (4.2%)	-	3 (10.7%)	-	
Radiographically findings of	on admission				
Abnormal lung finding	49 (69.0%)	26 (60.5%)	23 (82.1%)	0.07	
Lateral	17 (23.9%)	11 (25.6%)	6 (21.4%)	-	
Bilateral	31 (43.7%)	15 (34.9%)	16 (57.1%)	0.09	
GGO	37 (52.1%)	18 (41.9%)	19 (67.9%)	0.05	
Multifocal GGO	34 (47.9%)	17 (39.5%)	17 (60.7%)	0.09	
Consolidation	22 (31.0%)	9 (20.9%)	13 (46·4%)	0.03*	3·27 (1·15–9·30

Crazy-paving appearance	19 (26.8%)	8 (18.6%)	11 (39.3%)	0.1	
Nodular lesion	5 (7.0%)	4 (9.3%)	1 (3.6%)	0.64	
Laboratory findings on adm	nission				
AST > 38 (IU/L)	15 (21.1%)	6 (14.0%)	9 (32.1%)	0.08	
ALT > 45 (IU/L)	13 (18.3%)	6 (14.0%)	7 (25.0%)	0.35	
LDH > 230 (IU/L)	23 (32.4%)	13 (30.2%)	10 (35.7%)	0.8	
CRP > 1.0 (mg/dL)	42 59.2%)	23 (53.5%)	19 (67.9%)	0.32	
White blood cell count <4000 (/µL)	15 (21.1%)	9 (20.9%)	6 (21.4%)	1.00	
Platelet count <15 (×10 ⁴ /µL)	7 (9.9%)	5 (11.6%)	2 (7.1%)	0.7	
Lymphocyte count <1200 (/µL)	26 (36.6%)	10 (23.3%)	16 (57.1%)	0.005*	4·4 (1·57–12·32)

440 Data are presented as n (%), or median [interquartile range], unless otherwise specified.

441 Asterisk indicates statistical significance.

442 OR, odds ratio; 95% CI, 95% confidence interval; GGO, ground glass opacity; AST, aspartate

443 aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C reactive

444 protein



